CG Oncology, Inc. CGON
Regular-session close
After hours · Nov 19, 4:25 PM ET
- YTD
- +97.25%
- 1 year
- +92.25%
5D +12.95 (+18.77%)
- Market cap
- 7.32B
- Revenue (ttm)
- 6.17M
- EPS (ttm)
- -2.76
- Shares out
- 89.32M
- Forward P/E
- -27.74
- YTD return
- +97.25%
- 1-year return
- +92.25%
- 50-day average
- 68.51
- 200-day average
- 67.10
- Enterprise value
- 6.17B
- Volume
- 2.52M
- Avg volume
- 1.19M
- Open
- 84.03
- Previous close
- 80.00
- Day's range
- 79.96 – 84.22
- 52-week range
- 37.01 – 93.95
- Beta
- 0.35
- Analysts
- Strong Buy
- Price target
- 109.69 (+33.9%)
- Earnings date
- Feb 26, 2027
Key statistics
- Price / sales
- 1186.38
- Price / book
- 7.38
- Revenue growth
- -3.70%
- Free cash flow
- -119.27M
- Total cash
- 984.46M
- Total debt
- 9.24M
- Return on equity
- -28.29%
- Short % of float
- 10.50%
Fundamental scorecard
5 of 25 checks passed on CGON’s reported financials
5of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 87.00
- Target (mean)
- 109.69
- Target (high)
- 150.00
- Strong buy3
- Buy10
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 26, 2027
Expected Feb 26, 2027. Consensus EPS estimate -0.67688.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 26, 2027 | Dec 30, 2026 | -0.69 | — | — | — |
| Nov 6, 2026 | Sep 30, 2026 | -0.83411 | -0.64 | +0.19 | +23.27% |
| Aug 6, 2026 | Jun 30, 2026 | -0.66415 | -0.90 | -0.24 | -35.51% |
| May 8, 2026 | Mar 31, 2026 | -0.58 | -0.71 | -0.13 | -22.41% |
| Feb 27, 2026 | Dec 31, 2025 | -0.61 | -0.51 | +0.10 | +16.39% |
| Nov 14, 2025 | Sep 30, 2025 | -0.55902 | -0.57 | -0.01 | -1.96% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 19, 2026 | Guggenheim | main | Buy | Buy |
| Nov 18, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Nov 17, 2026 | JP Morgan | main | Overweight | Overweight |
| Nov 17, 2026 | Truist Securities | reit | Buy | Buy |
| Nov 17, 2026 | RBC Capital | down | Outperform | Sector Perform |
| Nov 17, 2026 | Wedbush | main | Outperform | Outperform |
About CG Oncology, Inc.
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Dallas, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cgoncology.com
News
Guggenheim Maintains Buy on CG Oncology, Raises Price Target to $120
Morgan Stanley Maintains Overweight on CG Oncology, Raises Price Target to $117
JP Morgan Maintains Overweight on CG Oncology, Raises Price Target to $113
Truist Securities Reiterates Buy on CG Oncology, Raises Price Target to $100
RBC Capital Downgrades CG Oncology to Sector Perform, Raises Price Target to $97
United Natural Foods To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday Wedbush Maintains Outperform on CG Oncology, Raises Price Target to $91
HC Wainwright & Co. Maintains Buy on CG Oncology, Raises Price Target to $115
CG Oncology Celebrates Defining Milestone As Bladder Cancer Trial Succeeds
CG Oncology Celebrates Defining Milestone As Bladder Cancer Trial Succeeds
Your note
Sign in to keep a note on CGON — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| KALOFONOS ISABEL | Officer | Purchase | Nov 17, 2026 | 0 |
| KUAN ARTHUR | Chief Executive Officer | Purchase | Nov 17, 2026 | 228,916 |
| LIU BRIAN GUAN-CHYUN M.D. | Director | Purchase | Jun 24, 2026 | 0 |
| MULAY JAMES J. | Director | Conversion of Exercise of derivative security | Jul 9, 2026 | 0 |
| POST LEONARD E | Director | Conversion of Exercise of derivative security | Nov 15, 2026 | 1,000 |
| SONG HONG FANG | Director | Sale | Sep 2, 2025 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RTW Investments LP | 9.53% | 8,514,590 | 697.34M | Sep 29, 2026 |
| T. Rowe Price Investment Management, Inc. | 7.53% | 6,726,945 | 550.94M | Sep 29, 2026 |
| Decheng Capital LLC | 7.13% | 6,371,669 | 521.84M | Sep 29, 2026 |
| Blackrock Inc. | 7.11% | 6,347,335 | 519.85M | Sep 29, 2026 |
| Wellington Management Group, LLP | 5.51% | 4,917,082 | 402.71M | Sep 29, 2026 |
| FMR, LLC | 5.14% | 4,594,462 | 376.29M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 3.20% | 2,860,428 | 234.27M | Jul 30, 2026 |
| T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 2.88% | 2,574,868 | 210.88M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.67% | 2,383,134 | 195.18M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.14% | 1,911,075 | 156.52M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.93% | 1,720,068 | 140.87M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.73% | 1,541,674 | 126.26M | Sep 29, 2026 |
